[FREE Report] 5 Growth Stocks Under $49
Stay focused on the long-term with these 5 growth stock picks.
Learn More.
Gwenn Hansen, insider at Nurix Therapeutics
Gwenn Hansen Insider Alerts

Get notified the next time Gwenn Hansen buys or sells Nurix Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Gwenn Hansen Insider Information

Insider of Nurix Therapeutics
Gwenn M. Hansen, Ph.D. has served as Chief Scientific Officer of Nurix since June 2020 and served as the company’s Senior Vice President, Research from July 2019 through May 2020. Since joining Nurix in 2015, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery in addition to leading the discovery organization. Prior to joining Nurix, Gwenn was an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and served in a variety of discovery-focused roles at Lexicon Pharmaceuticals. Dr. Hansen holds a B.A. in Biology from Gustavus Adolphus College and a Ph.D. in Biomedical Sciences from the University of Tennessee-Knoxville.

What is Gwenn Hansen's net worth?

The estimated net worth of Gwenn Hansen is at least $298,405.33 as of September 7th, 2021. Dr. Hansen owns 15,797 shares of Nurix Therapeutics stock worth more than $298,405 as of January 20th. This net worth evaluation does not reflect any other assets that Dr. Hansen may own. Additionally, Dr. Hansen receives an annual salary of $673,850.00 as Insider at Nurix Therapeutics. Learn More.

How old is Gwenn Hansen?

Dr. Hansen is currently 50 years old. There are 4 older executives and no younger executives at Nurix Therapeutics. The oldest executive at Nurix Therapeutics is Mr. Howard A. Simon J.D., Esq., SPHR, VP of Operations & Corp. Counsel, who is 62 years old. Learn More.

What is Gwenn Hansen's salary?

As the Insider of Nurix Therapeutics, Inc., Dr. Hansen earned a total compensation package of $1,552,577.00 in 2020. Dr. Hansen earned a salary of $391,250.00, a bonus of $97,600.00, options awards of $878,727.00, non-equity compensation of $181,500.00, and other compensation of $3,500.00.The highest earning executive at Nurix Therapeutics is Dr. Arthur T. Sands, CEO, Pres & Director, who commands a salary of $852,770.00 per year.

How do I contact Gwenn Hansen?

The corporate mailing address for Dr. Hansen and other Nurix Therapeutics executives is , , . Nurix Therapeutics can also be reached via phone at 415-660-5320 and via email at [email protected]

Has Gwenn Hansen been buying or selling shares of Nurix Therapeutics?

Gwenn Hansen has not been actively trading shares of Nurix Therapeutics over the course of the past ninety days. Most recently, Gwenn Hansen sold 400 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $29.13, for a transaction totalling $11,652.00.

Who are Nurix Therapeutics' active insiders?

Nurix Therapeutics' insider roster includes Pierre Beaurang (Insider), Gwenn Hansen (Insider), and Christine Ring (General Counsel).

Are insiders buying or selling shares of Nurix Therapeutics?

In the last twelve months, insiders at the sold shares 27 times. They sold a total of 63,630 shares worth more than $1,921,386.90. The most recent insider tranaction occured on December, 10th when General Counsel Christine Ring sold 1,200 shares worth more than $34,848.00. Insiders at Nurix Therapeutics own 6.3 % of the company.

Information on this page was last updated on 12/10/2021.

Gwenn Hansen Insider Trading History at Nurix Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2021Sell400$29.13$11,652.00View SEC Filing Icon  
11/1/2021Sell400$33.24$13,296.00View SEC Filing Icon  
10/27/2021Sell400$35.00$14,000.00View SEC Filing Icon  
10/1/2021Sell400$29.92$11,968.00View SEC Filing Icon  
9/7/2021Sell1,600$35.00$56,000.0015,797View SEC Filing Icon  
8/2/2021Sell400$31.21$12,484.0014,204View SEC Filing Icon  
6/1/2021Sell400$27.74$11,096.0014,204View SEC Filing Icon  
4/5/2021Sell400$35.00$14,000.0014,204View SEC Filing Icon  
4/1/2021Sell400$31.55$12,620.0014,204View SEC Filing Icon  
3/16/2021Sell800$45.00$36,000.0014,604View SEC Filing Icon  
3/1/2021Sell800$35.95$28,760.00View SEC Filing Icon  
See Full Table

Gwenn Hansen Buying and Selling Activity at Nurix Therapeutics

This chart shows Gwenn Hansen's buying and selling at Nurix Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nurix Therapeutics Company Overview

Nurix Therapeutics logo
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $18.89
Low: $18.70
High: $20.50

50 Day Range

MA: $28.29
Low: $18.89
High: $34.06

2 Week Range

Now: $18.89
Low: $18.70
High: $50.00


319,988 shs

Average Volume

396,538 shs

Market Capitalization

$842.74 million

P/E Ratio


Dividend Yield



Free Pick from Jeff Brown: “Buy S.C.G .”
Jeff Brown picked Tesla in 2018 before it jumped 1,390%. He picked Nvidia before it jumped 3,545%. And he picked Bitcoin before it skyrocketed 22,750%.

And now he’s saying S.C.G. will be the next big tech play. He’s not the only one. Apple’s CEO even called it “the next big thing.”
Click here and get the name and ticker symbol!